AMAFRICA, a patient-navigator program for accompanying lymphoma patients during chemotherapy in Ivory Coast: a prospective randomized study

Table 3 b. Discrepancies between referral and expert pathologists based on tissue section analysis

Nature of the discrepancy*	Number of cases
Low grade B cell lymphoma to diffuse large B cell lymphoma [1]	15
Unclassified T cell proliferation to classified lymphoma subtypes [2]	11
Unclassified lymphoma to classified lymphoma subtype [3]	10
Low grade B cell lymphoma reclassification [4]	8
NHL to HL [5]	3
Reactive lesion to NHL [6]	3
Total	50 /85** (58.8%)

*from provisional to expert diagnosis
**based on 85 biopsy specimens, the 15 remaining cases were characterized on the basis of circulating malignant cells analysis (morphology and immunophenotype)
Details of expert review [1]: 15 cases referred as FL (n = 5), CLL (n = 3), Burkitt lymphoma (n = 3) and PTCL (n = 4) were changed to DLBCL NOS [2]. 11 cases referred as unclassified T-cell lymphoproliferation to classified lymphoma subtype: ALCL (n = 2), PTCL (n = 1), T-ALL/LL (n = 4), HL (n = 3) and DLBCL NOS (n = 1) [3]. 10 unclassified lymphomas were classified in PTCL (n = 1); MZL (n = 6), MCL (n = 2), CLL (n = 1) [4]. This category includes MZL (n = 6) and MCL (n = 2) [5]. This category includes 3 NHL (3 DLBCL) that were changed to HL (n = 3) [6]; 3 reactive lesions were changed to HL (n = 2) and FL (n = 1)

ISSN: 1471-2407